Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 9/2014

Open Access 01-09-2014 | Letter

Once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis: reply to T. Kawada

Authors: T. Sugimoto, T. Nakamura, Y. Nakamura, Y. Isogai, M. Shiraki

Published in: Osteoporosis International | Issue 9/2014

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Sugimoto T, Nakamura T, Nakamura Y, Isogai Y, Shiraki M (2014) Profile of changes in bone turnover markers during once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis. Osteoporos Int 25:1173–1180
2.
3.
Shiraki M, Sugimoto T, Nakamura T (2013) Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women. Osteoporos Int 24:219–226PubMedCentralPubMedCrossRef
4.
Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441PubMedCrossRef
5.
Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Yoshikawa H, Nishizawa Y, Fujita T, Shiraki M (2012) Randomized teriparatide [human parathyroid hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 97:3097–3106PubMedCrossRef
6.
Prevrhal S, Krege JH, Chen P, Genant H, Black DM (2009) Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment. Curr Med Res Opin 25:921–928PubMedCrossRef
7.
Tsujimoto M, Uenaka K, Iwata A, Higashiuchi Y, Sowa H (2012) Effects of teriparatide in Japanese and non-Japanese populations: bridging findings on pharmacokinetics and efficacy. J Bone Miner Metab 30:326–337PubMedCrossRef
8.
Miyauchi A, Matsumoto T, Sugimoto T, Tsujimoto M, Warner MR, Nakamura T (2010) Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone 47:493–502PubMedCrossRef
Metadata
Title
Once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis: reply to T. Kawada
Authors
T. Sugimoto
T. Nakamura
Y. Nakamura
Y. Isogai
M. Shiraki
Publication date
01-09-2014
Publisher
Springer London
Published in
Osteoporosis International / Issue 9/2014
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-014-2722-5

Other articles of this Issue 9/2014

Osteoporosis International 9/2014 Go to the issue

Original Article

What analytic method should clinicians use to derive spine T-scores and predict incident fractures in men? Results from the MrOS study

Letter to the Editor

Cortisol and the muscle-bone axis

Original Article

Efficacy of zoledronic acid treatment in Paget disease of bone

Erratum

Erratum to: Incidence of second hip fracture and compliant use of bisphosphonate

Original Article

Effects of low intensity vibration on bone and muscle in rats with spinal cord injury

Letter to the Editor

Identifying coeliac disease in DXA referrals